Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

IBTR with the 1 mm and 2 mm cutoff found rates found the margin widths were small and not clinically meaningful.